Question 1

What are the most cited papers from ApoVax (United States)?

Accepted Answer

The most cited paper from ApoVax (United States) is "4-1BB Ligand as an Effective Multifunctional Immunomodulator and Antigen Delivery Vehicle for the Development of Therapeutic Cancer Vaccines" (Rajesh Kumar Sharma, Rich-Henry Schabowsky, Abhishek K. Srivastava et al., 2010), with 58 citations. Next come "A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity" (55) and "SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model" (39).

Question 2

Which research topics does ApoVax (United States) publish most on?

Accepted Answer

By volume in 2022-now: Cell Image Analysis Techniques, Molecular Biology Techniques and Applications, Spaceflight effects on biology and Escherichia coli research studies.

Question 3

Which fields of science does ApoVax (United States) work in?

Accepted Answer

In all years, 44% of research at ApoVax (United States) is in Life Sciences, 28% in Physical Sciences. Its largest fields are Medicine (24%), Biochemistry, Genetics and Molecular Biology (20%), Immunology and Microbiology (20%). It does 1.6× the world's share of Life Sciences.

Question 4

Is ApoVax (United States)'s research output growing?

Accepted Answer

Output in 2022-2025 was 35% higher than in 2018-2021.